In August, NICE announced a scoping exercise for zanubrutinib for Waldenstrom’s macroglobulinaemia (WM). This is the first early stage of the NICE appraisal process for assessing whether zanubrutinib will be made available for WM patients via the NHS in England. WMUK submitted a response, working together with Lymphoma Action.
Zanubrutinib is a new treatment manufactured by BeiGene. It is a BTK inhibitor (which inhibits B-cell proliferation and promotes cell death) and is taken orally, by tablet.
We are very keen to hear from any patients who are currently taking zanubrutinib in the UK. If you would be prepared to share your experiences to inform our work on a forthcoming NICE appraisal, please do get in touch by emailing us at email@example.com or call us on 020 3096 7858.